annual meeting program - American Society of Clinical Oncology

2:00 PM - 6:00 PM
GENERAL POSTER SESSION
Sunday, June 6, 2010
Gastrointestinal (Noncolorectal) Cancer
Location: S Hall A2
Tracks(s): Gastrointestinal (Noncolorectal) Cancer
Brd. 18A Linifanib phase II trial in patients with advanced hepatocellular carcinoma
(HCC). (Abstract #4038)
H. Toh, P. Chen, B. I. Carr, J. J. Knox, S. Gill, J. Qian, Q. Qin, J. L. Ricker,
D. M. Carlson, W. Yong
Brd. 18B Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in
combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced
pancreatic cancer. (Abstract #4039)
M. M. Javle, G. R. Varadhachary, R. T. Shroff, P. Bhosale, M. J. Overman,
J. Weatherly, R. A. Wolff, J. L. Abbruzzese
Brd. 18C Clinicopathologic characteristics of microsatellite instability (MSI) tumors in
resected gastric cancer patients. (Abstract #4040)
H. J. Cho, J. Kim, S. Im, M. Kim, S. Han, D. Oh, T. Kim, H. Yang, W. Kim, Y. Bang
Brd. 18D Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle
as second-line treatment for advanced or recurrent gastric cancer.
(Abstract #4041)
K. Chin, K. Kato, T. Yoshikawa, K. Yamaguchi, T. Esaki, Y. Tsuji, K. Sakai,
M. Kimura, R. Ikeda, Y. Matsumura
Brd. 18E Meta-analyses of randomized trials assessing the effect of neoadjuvant
chemotherapy in locally advanced gastric cancer. (Abstract #4042)
H. Li, F. Zhu, Y. Cao, L. Zhai, T. Lin
Brd. 18F KRAS, BRAF mutations, and HER2 expression in patients operated for
pancreatic adenocarcinomas. (Abstract #4043)
N. A. Schultz, A. Roslind, M. Heeran, I. J. Christensen, E. V. Høgdall, T. Horn,
M. Wøjdemann, E. Balslev, J. S. Johansen
Brd. 18G Prospective analysis of clinical outcomes and prognostic factors in patients
with neuroendocrine tumors (NETs). (Abstract #4044)
M. Ter-Minassian, C. S. Frauenhoffer, S. M. Hooshmand, K. Asomaning, X. Lin,
J. A. Chan, D. C. Christiani, M. Kulke
Brd. 18H Comparative effectiveness of radioembolization and the standard of care for
hepatocellular carcinoma: Is a randomized survival study feasible?
(Abstract #4045)
R. Salem, A. Riaz, R. Lewandowski, L. Kulik, M. Abecassis, M. F. Mulcahy
Brd. 19A Molecular predictors of response to antiangiogenic therapy in HCC: Data
from bevacizumab and erlotinib phase II study. (Abstract #4046)
A. O. Kaseb, J. Morris, M. Hassan, M. Iwasaki, L. Deaton, M. M. Javle,
E. Garrett-Mayer, G. Onicescu, J. L. Abbruzzese, M. B. Thomas
Brd. 19B Association of germline polymorphisms in genes involved in the CD44
pathway and clinical outcome in localized gastric adenocarcinoma (GA).
(Abstract #4047)
Y. Ning, T. Winder, D. G. Power, D. Yang, W. Zhang, P. O. Bohanes, G. Lurje,
L. H. Tang, M. A. Shah, H. Lenz
Brd. 19C (Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP)
versus XP/FP alone as first-line therapy for advanced HER2-positive gastric
cancer. (Abstract #4048)
H. C. Chung, Y. Bang, E. Van Cutsem, Y. Kang, Y. Hamamoto, V. Moiseyenko,
E. Gotovkin, A. Urspruch, P. Ducournau
267
SUNDAY